Knight Therapeutics (OTCMKTS:KHTRF) Trading Down 0.9% – Should You Sell?

Knight Therapeutics Inc. (OTCMKTS:KHTRF)’s stock price fell 0.9% on Thursday . The company traded as low as $6.89 and last traded at $6.8940. Approximately 6,276 shares were traded during trading, a decline of 24% from the average daily volume of 8,267 shares. The stock had previously closed at $6.96.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada reissued an “outperform” rating on shares of Knight Therapeutics in a research report on Friday, May 8th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

Knight Therapeutics Price Performance

The company’s 50-day simple moving average is $6.57 and its 200 day simple moving average is $5.46.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.